Catalent Inc (NYSE:CTLT) has been given a consensus rating of “Buy” by the sixteen ratings firms that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $45.75.
A number of equities research analysts have commented on the stock. Royal Bank of Canada set a $48.00 price target on shares of Catalent and gave the stock a “buy” rating in a report on Monday, February 5th. Stephens cut shares of Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target for the company in a report on Monday, November 6th. Finally, BidaskClub cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th.
In other news, Director Uwe Roehrhoff purchased 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, with a total value of $294,150.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.
Catalent (NYSE CTLT) traded up $0.77 on Friday, hitting $41.58. 632,613 shares of the stock traded hands, compared to its average volume of 970,323. Catalent has a 52 week low of $27.48 and a 52 week high of $47.87. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. The firm has a market capitalization of $5,415.41, a PE ratio of 72.14, a PEG ratio of 2.33 and a beta of 1.47.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to analysts’ expectations of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. Catalent’s revenue for the quarter was up 25.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.27 earnings per share. equities research analysts anticipate that Catalent will post 1.53 EPS for the current fiscal year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.